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Muscle mitochondrial metabolism is a tightly controlled process that involves the coordination of signaling pathways and factors
from both the nuclear and mitochondrial genomes. Perhaps the most important pathway regulating metabolism in muscle is
mitochondrial biogenesis. In response to physiological stimuli such as exercise, retrograde signaling pathways are activated that
allow crosstalk between the nucleus and mitochondria, upregulating hundreds of genes and leading to higher mitochondrial
content and increased oxidation of substrates. With type 2 diabetes, these processes can become dysregulated and the ability of the
cell to respond to nutrient and energy ﬂuctuations is diminished. This, coupled with reduced mitochondrial content and altered
mitochondrial morphology, has been directly linked to the pathogenesis of this disease. In this paper, we will discuss our current
understanding of mitochondrial dysregulation in skeletal muscle as it relates to type 2 diabetes, placing particular emphasis on the
pathways of mitochondrial biogenesis and mitochondrial dynamics, and the therapeutic value of exercise and other interventions.
1.Introduction
Type 2 diabetes is the most common form of diabetes
accounting for ∼90% of diabetic cases and ∼8% of the
total population [1]. Type 2 diabetes is characterized by
insulin resistance and is commonly associated with several
clinical complications such as hypertension, atherosclerosis,
and cardiovascular disease, and these are often collectively
referred to as the metabolic syndrome [1]. Although the spe-
ciﬁc molecular mechanisms underlying type 2 diabetes are
not well understood, insulin resistance is believed to result
from reductions in glucose transport and phosphorylation
and impaired fatty acid metabolism in a number of tissues,
notably skeletal muscle [1, 2]. Speciﬁcally, defects in this
seriesofreactionsaredirectlyassociatedwithincreasedlevels
of plasma and intracellular free fatty acids and alterations in
insulin signaling pathways [3, 4].
Mitochondriahaveseveralfunctionsbutaremostknown
fortheirroleaskeyregulatorsofmetabolicactivitywithinthe
cell by converting energy from the oxidation of macronutri-
ents to ATP. Mitochondrial activity and function in skeletal
muscle is a highly controlled process, under the inﬂuence
of a variety of nuclear and mitochondrial factors that
act as metabolic sensors and can adapt to perturbations
in cellular nutrient and energy status. The renewal of
mitochondria through the process of biogenesis is vital
for maintaining mitochondrial integrity, and a diminished
capacity for organelle biogenesis has been implicated in the
pathogenesis of several diseases such as aging, neurode-
generation, as well as type 2 diabetes [1, 5]. Additionally,
muscle mitochondrial metabolism is regulated by a group
of morphogenesis machinery proteins which are important
for mitochondrial fusion and ﬁssion events and also for
their independent eﬀects on bioenergetics, programmed2 Experimental Diabetes Research
cell death, and autophagy [6]. Defects in mitochondrial
biogenesis and morphogenesis factors can impair enzyme
activity and reduce the oxidative capacity of the cell leading
to insuﬃcient oxidation of lipids and increased intramy-
ocellular lipid (IMCL) levels. The inability of mitochondria
to utilize these substrates along with their accumulation
within muscle has been associated with impaired insulin
signaling pathways and reduced glucose uptake [7]. Elevated
IMCLs, in association with the increased production of lipid
metabolites such as acyl coenzyme A (CoA), diacylglycerol
(DAG), ceramides, and reactive oxygen species (ROS) [2,
8], can aﬀect insulin signaling and contribute to insulin
resistance associated with type 2 diabetes. Additionally,
skeletal muscle from individuals with type 2 diabetes have
a higher percentage of type II ﬁbers and a lower percentage
of type I ﬁbers when compared to control individuals [9, 10].
Type II ﬁbers have a reduced capacity to oxidize fat [11]a n d
possessuniquepropertiesthathavebeenshowntopotentiate
mitochondrial hydrogen peroxide production and oxidative
stress [12]. Therefore, there are likely multiple factors that
contribute to the stress environment that intensify the
mitochondrial dysregulation observed in type 2 diabetes.
The multiplicity of mitochondrial functions has made
it a logical target for the study of metabolic diseases, and,
given that skeletal muscle represents the major site of
insulin-stimulated glucose utilization in the body [13, 14],
dysregulation of mitochondria is closely associated with
insulin resistance and the pathogenesis of type 2 diabetes
in muscle. In this paper, we will ﬁrst discuss key pathways
involved in the regulation of mitochondria, with speciﬁc
attention given to organelle biogenesis, as well as mito-
chondrial fusion and ﬁssion events and their contribution
to metabolic perturbations in muscle. In the second part,
current therapeutic interventions will be described, with
the focus on those related to stimulating mitochondrial
biogenesis.
2. MitochondrialBiogenesis
Skeletal muscle is a malleable tissue and can adapt to
alterations in energy status and substrate supply in part
via its ability to increase the number of mitochondria.
Mitochondrial biogenesis is induced by numerous physi-
ological, environmental, and pharmacological stimuli and
results from the transcription and translation of genes both
in the nuclear and the mitochondrial genomes [15, 16]. The
biogenesis of mitochondria is mediated by changes in many
key intracellular events, including transcriptional activation,
mRNA stability, posttranslational modiﬁcation of proteins,
and/or alterations in the import and processing of proteins
in mitochondria (Figure 1)[ 17, 18]. These gene products are
assembled into functional multisubunit complexes within
mitochondria and enhance oxidative capacity and ATP
production within the cell. Thus, mitochondria are key
regulators of metabolic activity within the cell, and it is these
attributes that have made mitochondria a primary focus in
the study of metabolic disorders such as type 2 diabetes.
Some of the early studies examining mitochondrial func-
tion and insulin resistance reported reduced mitochondrial
content and impaired lipid oxidation in skeletal muscle
of obese and type 2 diabetic individuals [19, 20]. The
role of mitochondria in obesity and type 2 diabetes has
been conﬁrmed by studies examining insulin resistant but
otherwise, healthy individuals, with non-insulin-resistant
subjects. The insulin-resistant group did not only have
higher intramyocellular lipid (IMCL) levels than the control
group, but this was associated with a 40% decrease in
both oxidative capacity and ATP levels [21]. Impaired
mitochondrial oxidative capacity is also an early feature
observed in insulin-resistant oﬀspring of individuals with
type 2 diabetes [22]. The altered mitochondrial phenotype
observed in human skeletal muscle tissue is retained in
myocyte cultures obtained from individuals with type 2
diabetes [23]. Furthermore, an A3243G mutation in the
tRNALeu gene in mitochondrial DNA (mtDNA) is the cause
of maternally inherited diabetes and deafness (MIDD), and
individuals with this mutation will likely develop diabetes
as they age [24]. These data support the hypothesis that
mitochondrial dysfunction may be one of the early events
in the pathogenesis of this disease that predisposes an
individual to elevated levels of IMCL, lipid metabolites, and
insulin resistance.
In order to elucidate the molecular mechanisms that
are responsible for the reduction in mitochondrial content
and enzyme activity, earlier studies used DNA microarray
techniques to examine the gene expression proﬁle of mito-
chondrial proteins within skeletal muscle of obese and type 2
diabetic patients. These studies found signiﬁcant alterations
in a wide array of genes responsible for glucose uptake, fatty
acid oxidation, and oxidative phosphorylation (OXPHOS)
[25, 26]. These include changes in the expression of var-
ious nuclear regulatory proteins. Peroxisome proliferator-
activated receptor γ (PPARγ) coactivator-1 (PGC-1) and
their related family members (PGC-1α,P G C - 1 β,P R C ,a n d
PERC) [27–30] are perhaps among the most well-known
regulators of mitochondrial biogenesis. In particular, PGC-
1α binds and coactivates transcription factors such as the
estrogen-related receptor alpha (ERRα) and the nuclear
respiratory factors 1 and 2 (NRF-1 and NRF-2) to cause the
induction of a broad spectrum of genes involved in substrate
metabolism and mitochondrial biogenesis. NRF-1 and NRF-
2 have been shown to transactivate target genes involved
in several mitochondrial processes, including OXPHOS sub-
units, heme biosynthesis, mitochondrial import machinery,
and mtDNA transcription [31–33]. In addition, it has been
shown that a dominant negative allele of NRF-1 prevents
the ability of PGC-1α to induce mitochondrial proliferation,
conﬁrming the importance of NRF-1 in PGC-1α-driven
mitochondrial biogenesis [29].
In skeletal muscle, the importance of PGC-1α has been
reinforced with data from studies in both cell culture, as well
as transgenic mouse models, where PGC-1α levels were ex-
perimentally altered. Forced expression of PGC-1α in cul-
turedmusclecellsandcardiac myocytesresultsin anincrease
in nuclear and mitochondrial gene expression and mtDNA
content [29, 34]. Animals with increased muscle PGC-1α
have a longer lifespan that is associated with enhanced
mitochondrial function, improved insulin sensitivity, andExperimental Diabetes Research 3
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Figure 1: Proposed model of mitochondrial biogenesis. In response to a stimulus such as skeletal muscle contractile activity or exercise,
intracellular Ca2+ levels, as well as AMP levels, increase leading to the activation of signaling molecules including AMP-activated protein
kinase (AMPK). These signaling pathways converge and interact primarily with the transcriptional coactivator peroxisome proliferator-
activated receptor-γ coactivator-1α (PGC-1α) which is a master regulator of mitochondrial biogenesis. PGC-1α activates its own expression,
as well as the expression of the nuclear respiratory factor-1 and 2 (NRF-1/2). Additionally, PGC-1α has recently been shown to be
deacetylated and activated by the longevity protein sirtuin 1 (SIRT1). NRF-1 and NRF-2 bind and upregulate the expression of nuclear
genes encoding mitochondrial proteins (NUGEMPs), as well as the expression of mitochondrial transcription factor A (Tfam). Tfam
along with other newly transcribed NUGEMPS are targeted and imported into mitochondrial subcompartments via the protein import
machinery (PIM). Within the matrix, Tfam binds to mtDNA and regulates the expression of the 13 mitochondrial DNA (mtDNA) gene
products. These proteins are assembled into multisubunit enzyme complexes within the electron transport chain (ETC) and mediate
oxidative phosphorylation (OXPHOS) and the production of ATP. Thus, coordinated expression regulated by the two genomes allows for
the proper assembly and expansion of the mitochondrial reticulum leading to mitochondrial proliferation and increased mitochondrial
number/content. Another important product of the ETC is reactive oxygen species (ROS) that are associated with the mitochondrial
membrane potential (Δψm). Elevated levels of ROS have been shown to activate mitochondrial outer membrane permeabilization (MOMP)
and the release of proapoptotic factors such as cytochrome c (Cyt c) into the cytosol that can subsequently activate caspase-dependent
signaling cascades leading to mitochondrially-mediated apoptosis. Furthermore, organelle biogenesis requires a continuous cycle of fusion
and ﬁssion events. Mitochondrial fusion of the outer and inner mitochondrial membranes is mediated by the GTPase proteins, mitofusin
1 and 2 (Mfn1 and Mfn2) and OPA1, respectively. Conversely, mitochondrial ﬁssion requires Drp1 and Fis1 which assemble at ﬁssion sites
on the mitochondrial membrane and induce membrane division. It has been proposed that ﬁssion can lead to mitochondria with diﬀerent
Δψm and that damaged or depolarized organelles will exit the fusion and ﬁssion cycle and will be removed through autophagy.4 Experimental Diabetes Research
reduced oxidative damage and also show resistance to age-
related weight gain [35]. Furthermore, overexpression of
PGC-1α in mice results in a partial ﬁber-type transition
from white muscle with mostly glycolytic ﬁbers to muscle
that appears red and has a high oxidative capacity [36].
This ﬁber-type conversion coincides with the activation of
calcineurin signaling cascades, the coactivation of myocyte-
enhancer factor 2 (MEF2) by PGC-1α, and the induction of
slow gene expression pathways. Calcium- (Ca2+-) dependent
PGC-1α activation was further conﬁrmed in skeletal muscle
from transgenic mice overexpressing a constitutively active
form of the calcium/calmodulin-dependent protein kinase
IV (CaMKIV). These mice displayed increased mtDNA
copy number and an upregulation of several enzymes that
are involved in fatty acid oxidation and OXPHOS [37].
Additionally, upregulation of PGC-1α mRNA and protein
with acute and chronic exercise in both animals and humans
leads to an increased mitochondrial content through the
induction of NRF proteins and mitochondrial transcription
factor A (Tfam) [38–40].
Regardingmetabolic disorders,PGC-1α mRNAlevelsare
reduced in certain cohorts of obese and type 2 diabetic indi-
viduals [25, 26], and, in some populations, polymorphisms
in the PGC-1α gene have been linked to a predisposition
for type 2 diabetes [41, 42]. PGC-1α induces the expres-
sion of the insulin-sensitive glucose transporter (GLUT4)
by interacting and coactivating the MEF2 transcription
regulator [43]. Furthermore, the tissue-speciﬁc knockout
of Tfam in pancreatic β cells leads to the development
of diabetes that is associated with a loss of mtDNA and
impaired oxidative capacity [44]. Despite these ﬁndings, the
importance of PGC-1α and other mitochondrial regulators
of biogenesis in insulin resistance and type 2 diabetes has
remained controversial. This is because several studies have
shown elevated IMCL levels and reduced mtDNA content
in the absence of changes in PGC-1α expression (mRNA
or protein) or other PGC-1α-related target genes [22, 45,
46]. In addition, several studies of muscle-speciﬁc PGC-
1α and/or PGC-1β null mice have demonstrated normal
glucose tolerance and insulin sensitivity [47, 48]. These
studies suggest that alternate mechanisms may also regulate
mitochondrial content in metabolic diseases. Clearly more
work is required in this area to obtain a better understanding
of the molecular pathways mediating insulin sensitivity in
both healthy muscle, as well as muscle with metabolic
dysfunction.
Another clue into the molecular function of PGC-1α
comes with the recent ﬁnding that PGC-1α is present within
mitochondria and speciﬁcally localized in a complex with
Tfam in mtDNA nucleoids [49]. This surprising ﬁnding is
also conﬁrmed in animals where, following an acute bout of
exercise, PGC-1α protein was increased in both the nuclear
and mitochondrial subfractions [50]. These preliminary
studies suggest that PGC-1α coactivates mitochondrial tran-
scriptioninboththenucleusandmitochondriaandindicates
the potential of PGC-1α as being a central messenger of
nuclear-mitochondrial crosstalk during cellular stress.
Recently, another family of proteins has emerged as
crucial regulators of mitochondrial activity and cellular
energy metabolism. Sirtuins are a group of class III his-
tone/protein deacetylases that are primarily known for their
involvementinpromotinglifespaninanumberoforganisms
including yeast, ﬂies, and mice, and they accomplish this
by the acetylation and deacetylation of target genes [51].
To date, seven sirtuin mammalian homologs have been
identiﬁed (SIRT1-7), three of which are mainly localized
to mitochondria (SIRT3, SIRT4, SIRT5) [51, 52]. SIRT1 is
a NAD-dependent deacetylase that is widely expressed in
mammalian cells and activated in response to cellular stress
conditionssuchaswithexercise,caloricrestriction(CR),and
starvation [53–57]. Transgenic mice overexpressing SIRT1
have similar physiological and behavioral phenotypes as
calorie restricted mice. These animals have less body fat,
are more metabolically active, and display improved insulin
sensitivity and glucose tolerance [58]. The CR-mediated
phenotype is dependent on SIRT1, since knockout of this
gene diminishes these adaptations [59]. Studies investigating
the role of SIRT1 in diabetes and skeletal muscle are limited.
In cardiac muscle of Otsuka Long-Evans Tokushima fatty
(OLETF) rats, SIRT1 levels were lower in these animals than
in control rats. Treatment with pioglitazone, a PPARγ ago-
nist, enhanced SIRT1 expression [60]. Similar attenuations
in SIRT1 levels were reported in adipocytes from ob/ob mice
[61] and adipose tissue from obese women [62]. SIRT1 gain-
of-function studies in various models of insulin resistance
and diabetes have revealed improved glucose tolerance and
decreased energy expenditure that is due to lower hepatic
glucose production and increased adiponectin levels [63]
suggesting that SIRT1-mediated longevity may be related to
improvements in insulin sensitivity.
SIRT1 regulates AMP activated-protein kinase (AMPK),
a key energy-sensing molecule that is activated during con-
ditions of low ATP and high AMP (increased AMP/ATP
ratio) such as with exercise [64] and CR [65]. Interestingly,
both SIRT1 and AMPK together or independently activate
PGC-1αtoinducetheexpressionofgenesinvolvedinglucose
and fatty acid metabolism and restore ATP levels [66–69].
AMPKactivitylevelsdeclinewithaging,andthisisassociated
withreducedinsulinsensitivityanddiminishedfattyacidox-
idation, suggesting that AMPK is an important regulator of
mitochondrial metabolism in muscle [70, 71].
More recently, another histone/protein deacetylase has
gained increasing attention as a key regulator of metabolic
activity in muscle. SIRT3 contains a cleavable N-terminal
mitochondrial targeting signal that permits its import into
mitochondrial subcompartments [51]. SIRT3 levels were
diminished with aging and a high fat diet [65, 72]a n d
increased in response to exercise, CR, and fasting [65, 72,
73]. It is likely that, similar to SIRT1, SIRT3 is a key reg-
ulator of muscle adaptation since it also targets PGC-1α
and inﬂuences mitochondrial transcriptional regulation in
muscle [65, 74].
It is important toremember thatskeletal muscle contains
two subpopulations of mitochondria, subsarcolemmal (SS)
and intermyoﬁbrillar (IMF) mitochondria, that display key
diﬀerences in biochemical and functional properties [75].
These diﬀerences are crucial because it has been proposedExperimental Diabetes Research 5
that, due to their close proximity to myonuclei, SS mito-
chondria may be important for driving processes at the
cell surface, including the propagation of insulin signaling
pathways, fatty acid oxidation, and glucose transport [75,
76]. In contrast, IMF mitochondria are thought to provide
energy for muscle contractions [75]. In both SS and IMF
subfractions, electron transport chain (ETC) activity was
reducedinobeseandtype2diabeticsubjectswhencompared
to lean subjects [77]. Interestingly, the decrement in enzyme
activity was more pronounced in the SS, compared to the
IMF subfraction, suggesting that SS mitochondria may be
more readily aﬀected in states of altered glucose home-
ostasis. These data are consistent with previous ﬁndings
showing that SS mitochondria are more labile in response to
metabolic changes [78, 79].
3. MitochondrialFusion and Fission
The adaptability of skeletal muscle is also associated with
mitochondrial morphological plasticity. Mitochondria are
dynamic and readily adapt to changes in cellular energy
demands through network remodeling and continuous
fusion and ﬁssion [5, 80]. Under normal conditions, mito-
chondrial fusion results in the formation of an inter-
connected mitochondrial network that allows the mixing
and redistribution of proteins and mtDNA and which has
been hypothesized to prevent the accumulation of mutated
o rd a m a g e dm t D N Ai nac e l l[ 5, 81, 82]. In contrast,
mitochondrial ﬁssion leads to mitochondria with a frag-
mented morphology facilitating the segregation of damaged
mitochondria that can then be targeted for degradation via
autophagy [5]. Although the molecular mechanisms mediat-
ing these morphological changes remain largely unknown,
recent studies have identiﬁed distinct fusion and ﬁssion
machinery that appear to regulate these processes [5, 81, 82].
The fusion of mitochondria in mammalian cells is
mediated by several proteins, the most well known being
the nuclear-encoded dynamin-related guanosine triphos-
phatases (GTPase), mitofusin 1 (Mfn1), and mitofusin 2
(Mfn2). Although these mitofusins share greater than 70%
homology, they have diﬀerent GTPase activity levels and
display distinct expression patterns, with Mfn2 present in
higher amounts in tissues such as heart and skeletal muscle
[83, 84]. Additionally, mutations in Mfn2 cause Charcot-
Marie-Tooth (CMT) disease-type 2A, the most common
form of CMT disease and an inherited neuropathy leading
to progressive weakness and sensory loss [85, 86]. While
mitofusins are responsible for tethering and fusion of the
outer mitochondrial membrane, another dynamin family
GTPase, Optic Atrophy 1 (OPA1), is required for inner
membrane fusion. OPA1 was ﬁrst identiﬁed through its
involvement in the neurodegenerative disease known as
autosomal dominant optic atrophy (ADOA) [87]. Alter-
native splicing of OPA1 produces multiple variants that
are distinctly present in diﬀerent species and tissues [88].
Furthermore, posttranslational modiﬁcation of OPA1 by
mitochondrial processing peptidase (MPP) results in dif-
ferent length isoforms that vary based on their localization
a n df u n c t i o n[ 89, 90]. Muscle-speciﬁc Mfn1 and Mfn2
knockout mice with a diminished capacity for mitochondrial
fusion have impaired mitochondrial function and a loss
of muscle mass that are associated with increased mtDNA
point mutations and deletions and severe mtDNA depletion
[91]. Similarly, silencing of OPA1 in mammalian cells
blocked mitochondrial fusion and resulted in mitochondrial
fragmentation, decreased OXPHOS, poor cell growth, and
reduced mitochondrial membrane potential (Δψm)[ 92].
These data indicate that mitochondrial fusion is important
for maintaining the integrity of the organelle by allowing
the intramitochondrial exchange of damaged mitochondria,
preventing their localization within speciﬁc organelles and
their accumulation within the cell.
Mitochondrial homeostasis is also regulated by ﬁssion
machinery such as dynamin-related protein 1 (DLP1/Drp1)
and ﬁssion protein 1 (Fis1). Drp1 is a dynamin-related
GTPase that is found in the cytosol and recruited by Fis1
to scission sites on the mitochondrial outer membrane to
induce mitochondrial ﬁssion. Downregulation of Drp1 in
HeLa cells leads to a loss in mtDNA, reduced mitochon-
drial respiration, and higher levels of ROS, all of which
are associated with mitochondrial dysfunction [93]. Also,
blockingﬁssionbyreducingthelevelsofDrp1andFis1genes
in a human cell line with a mtDNA mutation exacerbates
the abundance of mutant mtDNA compared with wild-type
mtDNA [94]. These studies imply that mitochondrial fusion
and ﬁssion are involved in mtDNA quantity and quality
control and are required for the maintenance of healthy
organelles.
It is also becoming more and more apparent that mito-
chondrial morphology is directly linked to mitochondrial
function and substrate utilization. Cells with a high mito-
chondrial fusion capacity display interconnected mitochon-
dria associated with increased OXPHOS, while cells with
high mitochondrial ﬁssion have fragmented mitochondria
and rely more on anaerobic metabolism pathways for energy
[81].Ahallmarkofmitochondrialbiogenesisisanexpansion
of the mitochondrial reticulum, thereby allowing the propa-
gation of signaling pathways and the mixing of metabolites.
A perfect example of this adaptation in muscle occurs with
exercise, whereby repeated bouts of an exercise stimulus
lead to muscle adaptations. Substantial evidence in the last
decade has shown the involvement of mitochondrial net-
work remodeling in these exercise-induced adaptations. The
expression levels of Mfn1, Mfn2, and Fis1 have been shown
to be increased in skeletal muscle following an acute bout of
exercise in both animals and humans [95, 96]. Additionally,
transcript levels of mitochondrial dynamics proteins are
upregulated with endurance exercise in healthy subjects, and
these are closely correlated with muscle OXPHOS activity
and PGC-1α mRNA content [97]. An important ﬁnding of
these studies is that fusion and ﬁssion machinery respond
rapidly to an exercise stimulus and that the levels of these
proteins are dependent on the type of exercise [95, 96].
Given the involvement of mitochondrial dynamics in
muscle metabolism, perturbations in the fusion-ﬁssion bal-
ance caused by changes in the levels of the molecular ma-
chinery have been shown to lead to abnormal mitochon-
drial morphology and to negatively impact mitochondrial6 Experimental Diabetes Research
function. Mitochondrial gene expression proﬁles and func-
tion are associated with changes in overall mitochondrial
morphologyinskeletalmusclefromdiabeticrats[83],aswell
as in humans with type 2 diabetes [83, 98]. In particular,
mitochondria in skeletal muscle from type 2 diabetics are
smaller in size than mitochondria present in lean subjects,
and they also contain abnormal cristae structure that would
suggest defects in the inner membrane [83, 98, 99]. In
our laboratory, we have found reduced levels of fusion
proteins Mfn2 and Opa1, but no alterations in ﬁssion
proteins Drp1 or Fis1 in skeletal muscle from type 2 diabetic
individuals (Figure 2(a)). Similar reports of decreased Mfn2
expression and aberrant mitochondrial morphology have
been documented by other studies in type 2 diabetics [98,
99].
Loss of function of the fusion protein Mfn2 leads to
impaired mitochondrial metabolism and is associated with
reduced mitochondrial oxygen consumption, membrane
potential, and glucose metabolism in a variety of tissues
[83, 92, 100]. In contrast, Mfn2 gain of function increases
substrateoxidationandimprovesmitochondrialmetabolism
in HeLa cells [100]. Additionally, similar to other key
metabolic factors, Mfn1 and Mfn2 are increased in response
to weight loss and exercise in healthy, obese, and type 2
diabetic individuals [95, 101] and are increased also in mice
subject to CR in mice [102]. This is dependent primarily on
PGC-1α and ERRα transactivation of the Mfn2 promoter,
suggesting that fusion is an important signaling event for
mitochondrial biogenesis and healthy insulin signaling in
muscle [95, 103]. Additionally, reduced levels of OPA1
are associated with insulin resistance in several cell types
[104], as well as in human ﬁbroblasts from patients with
ADOA with impaired OXPHOS and reduced mitochondrial
fusion events [105]. These ﬁndings are in keeping with
the observation that mitochondrial fusion is an important
signaling event for mitochondrial biogenesis in muscle. For
the most part, the regulatory mechanisms and the functional
importance of these protein changes in obesity and type 2
diabetes remain enigmatic, and more work is required to
elucidatetheregulatoryfactorsoftheotherfusionandﬁssion
machineries.
3.1. Mitochondrial Dynamics and Cell Death. The ﬁnding
that aberrant mitochondrial morphology is present in cells
undergoing apoptosis has led to the examination of the
possible link between mitochondrial fusion and ﬁssion pro-
cessesandprogrammedcelldeath.Ahallmarkofapoptosisis
mitochondrial outer membrane permeabilization (MOMP)
and the release of cytochrome c that activates proapoptotic
signaling cascades. This results in the fragmentation of DNA
[106]. Imaging experiments have demonstrated that mito-
chondrial fragmentation occurs concurrently with MOMP.
This is primarily due to ﬁssion, since either the inhibition
of ﬁssion proteins or upregulation of fusion proteins can
delay or prevent mitochondrial fragmentation, along with
the induction of proapoptotic signaling events including
MOMP, cytochrome c release, and cell death [89, 107].
Studies conducted to elucidate the molecular mecha-
nisms responsible for the association between mitochondrial
morphology and apoptosis revealed a physical interaction
between morphogenesis proteins and the apoptosis machin-
ery. In particular, proapoptotic proteins such as Bax and
Bak interact with Mfn proteins [108, 109], and similar
ﬁndings were reported between the ﬁssion machinery and
the Bcl-2 family of proteins [110, 111]. It is highly likely
that the physical interaction between apoptotic proteins and
mitochondrial morphogenesis proteins is another means of
regulating cell death. However, not all studies are consistent
with this theory, and more work is required to clearly show
whether mitochondrial fusion and ﬁssion are an important
part of the apoptosis signaling cascade. Nonetheless, altering
levels of fusion and ﬁssion events can confer protection
to the cell, and this introduces a potential mechanism of
decreasing apoptotic susceptibility through the modulation
of the fusion and ﬁssion machinery.
Mitochondria represent the major source of ROS pro-
duction within the cell and increased levels of ROS are
a likely culprit in a variety of pathophysiological condi-
tions, including type 2 diabetes. Increased ROS production
was associated with altered mitochondrial morphology in
myotubes cultured in high glucose conditions, as well as
in diet-induced diabetic mice [112]. Furthermore, increased
oxidative stress within mitochondria arising from impaired
oxidative metabolism may contribute to greater lipid perox-
idation and damage to cell membranes and DNA, activating
a cascade of signaling events that further exacerbate the
severity of the disease [113]. A number of studies have found
that altering mitochondrial fusion and ﬁssion events can
inﬂuence ROS production in mitochondria. For instance,
increasingmitochondrialfusionordecreasingmitochondrial
ﬁssion during hyperglycemia can prevent mitochondrial
fragmentation and reduce ROS levels in the cell [107].
Treatment of cells with hydrogen peroxide, antimycin A, or
rotenone to increase ROS production resulted in fragmented
mitochondria [107, 114], while addition of an antioxidant
reduced ROS levels and inhibited mitochondrial fragmen-
tation [115]. The eﬀect of mitochondrial fusion and ﬁssion
machinery on apoptosis is likely associated with its ability
to modulate ROS levels. Thus, mitochondrial dynamics is
a relatively new ﬁeld in mitochondrial biology, and despite
growing progress, many questions still remain regarding
how alterations in mitochondrial shape aﬀect mitochondrial
bioenergetics, morphology, and ROS production, as well as
the sequential order of these events in skeletal muscle with
obesity and type 2 diabetes.
Furthermore, a growing area of interest in the ﬁeld of
metabolic diseases is the study of obesity in the elderly, the
prevalenceofwhichhasconsiderablyincreasedinthelastfew
years [116, 117]. As we age, there is a progressive decline in
muscle mass and strength, as well as an increased fat mass.
Thiscombinationofsarcopeniaandobesityhasrecentlybeen
deﬁned as “sarcopenic obesity” [116, 117]. While the molec-
ular mechanisms mediating a loss of muscle mass in obesity
and type 2 diabetes are unknown, several theories, including
increased apoptosis, have been brought forward. Recently,Experimental Diabetes Research 7
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Figure 2: (a) Mitochondrial morphology proteins in type 2 diabetes. The research volunteers that participated in this study were obese
subjects with type 2 diabetes undergoing coronary bypass surgery and were all male between 48 and 75 years of age. Biopsies from the vastus
medialis muscle were removed from both control and type 2 diabetic subjects from within incisions of the inner thigh and protein analyses
performed. The protocol was approved by the Medical Ethics Committees of Laval University and Laval Hospital, and all subjects provided
informed written consent. Representative western blots of fusion proteins Mfn2 and OPA1 and ﬁssion proteins Drp1 and Fis1 from the
vastus medialis muscle of control (Con) and type 2 diabetic subjects (Dia). A summary of repeated experiments is shown below with values
expressed as a fold over control. Values are means ± SE; n = 4–9; ∗P<0.05 versus Con. (b) Indicators of apoptotic susceptibility in type
2 diabetes. Western blots of the antiapoptotic protein Bcl-2 and the proapoptotic protein Bax in vastus medialis muscle of Con and Dia
individuals and the graphical representation of the data is shown below. Values are means ± SE; n = 4–9. (c) The ratio of Bax/Bcl-2 in Dia
subjects when compared to Con.
Sishi et al. [118] have demonstrated that, as a result of diet-
induced obesity, skeletal muscle of adult rats displayed mus-
cle atrophy along with increased apoptosis. This was evident
by increased levels of caspase-3 and poly(ADP-ribose) poly-
merase (PARP), two hallmark features of cell death. Addi-
tionally, electron micrographs of muscle ﬁbers from obese
and type 2 diabetic individuals display an altered mitochon-
drial structure and fragmented mitochondria, indicating the
potential involvement of apoptosis [99]. We have obtained
similar results of increased apoptotic signaling, with a trend
toward higher levels of the proapoptotic protein Bax and
lower levels of the antiapoptotic protein Bcl-2 observed in8 Experimental Diabetes Research
muscle from type 2 diabetics (Figure 2(b)). This indicates a
greaterBax/Bcl-2ratio(Figure 2(c))andsuggeststhatmuscle
from type 2 diabetics has a greater susceptibility to apoptosis
when compared to healthy individuals. Although these
studies point to the involvement of apoptosis in sarcopenic
obesity, much more research is required to characterize
apoptotic signaling pathways in obesity and type 2 diabetes.
3.2. Mitochondrial Dynamics and Autophagy. Mitochondrial
dynamics are also involved in another form of cell death
known as autophagy. Autophagy protects the cell through
the selective degradation and recycling of organelles such
as mitochondria by lysosomal machinery [119, 120]. Under
normal conditions, autophagy prevents the accumulation
of damaged mitochondria within the cell that can trigger
apoptotic pathways and irreversible cell death. Autophagy is
particularly important for postmitotic tissues such as skeletal
muscles that are exposed to high levels of oxidative stress and
that do not have an inherently high capacity for regeneration
[119, 120].
Recent studies have shed light on the function and
regulation of autophagic pathways in skeletal muscle and
have implicated the involvement of mitochondrial ﬁssion.
The monitoring of individual mitochondria in cultured cells
has revealed that daughter mitochondria generated by mi-
tochondrial ﬁssion display diﬀerent mitochondrial mem-
brane potentials (Δψm), with one mitochondrion possessing
ah i g hΔψm and the other a low Δψm. Interestingly enough,
depolarized mitochondria with a lower Δψm were selectively
degradedbyautophagyanddisplayedalowerfusioncapacity
when compared to mitochondria with a high Δψm.T h e
reduced capacity for fusion in this subpopulation of mito-
chondria was attributed to low levels of the OPA1 protein
[104]. Increased autophagy levels have also been reported in
Fis1-overexpressing cells, indicating the potential for both
fusion and ﬁssion events in regulating autophagy signaling
pathways and mitochondrial turnover [121].
Reduced autophagy has been reported in several tissues
with age [122–124], and this is associated with the presence
of enlarged mitochondria. In a recent study conducted
by Masiero and Sandri [125], muscle-speciﬁc knockout of
the autophagy-related protein 7 (Atg7) resulted in muscle
loss and weakness associated with abnormal mitochondria
and the accumulation of protein aggregates and vacuoles.
Impaired glucose homeostasis and abnormal mitochondrial
structure were also observed in Atg7-deﬁcient pancreatic β
cells [126]. Furthermore, electron micrographs of muscle
ﬁbers from obese and type 2 diabetic subjects revealed that
mitochondria are smaller and contain abnormal inner mem-
branestructurewhencomparedtomuscleformleansubjects
[83, 98]. Additionally, the presence of vacuole-like structures
which, when stained with a membrane marker, contain frag-
mented mitochondria could be detected [99]. Whether these
vacuoles represent autophagosomes engulﬁng damaged or
energy-deﬁcient mitochondria still requires con-ﬁrmation.
These studies suggest that the clearance of damaged proteins
and organelles such as mitochondria is vital for maintaining
cellular integrity. Whether the dysregulation of autophagy
contributes to the pathogenesis of type 2 diabetes remains
to be investigated.
4. Mitochondrial-MediatedTherapeutic
Interventions
As mentioned above, factors involved in mitochondrial
biogenesis are vital for tissue-speciﬁc metabolic control,
and recent research has focused on modalities that can
improve mitochondrial function and substrate oxidation by
stimulating mitochondrial biogenesis and nutrient-sensing
pathways. These include physiological and macronutrient
interventions, as well as pharmacological interventions.
4.1. Physiological and Macronutrient Interventions
4.1.1. Exercise and Weight Loss. Skeletal muscle from obese
and type 2 diabetic individuals is characterized by an
impaired oxidative capacity and increased IMCL content
[127, 128]. Recent studies to identify potential therapeutic
modalities in obese/type 2 diabetic individuals have shown
the eﬀectiveness of both acute and chronic exercise to
increase muscle glucose disposal, fatty acid oxidation, and
mitochondrial biogenesis [129–131]. These changes are
mediated by key metabolic factors such as AMPK and SIRT1
that are stimulated with reduced energy states and directly
activate the PGC-1α-mediated induction of target genes,
including NRF-1, Tfam, and Mfn2, as well as genes involved
in glucose and fatty acid oxidation [69, 95, 96, 130]. Obese
and type 2 diabetic individuals have impaired activation of
these signaling pathways, and their responses are attenuated
when compared to healthy subjects suggesting that a higher
intensity and/or duration of exercise is required to achieve
the same adaptations in these patients [130, 132].
Weight loss alone is associated with a reduction in
IMCL content [20, 133]. However, the beneﬁcial eﬀects of
exercise on insulin resistance occur in the absence of a
change in lipid content and active lipid intermediates (e.g.,
ceramides, DAGs, CoAs) and in some cases even elevated
IMCL levels [134, 135]. In a study conducted by He et al.
[136] using a combination of weight loss and moderate-
intensity exercise, increased insulin sensitivity was associated
with a reduction in the size of the lipid droplets within
skeletal muscle and not the total amount of lipid. The
reduced size of the lipid droplets was linked to an improved
aerobic capacity, suggesting that increased oxidative enzyme
activity resulting from physical activity allowed for the more
eﬃcient oxidation of lipids. This is consistent with studies of
trained athletes that have been reported to have higher IMCL
levels, coinciding with greater oxidative enzyme capacity
and improved insulin sensitivity [137, 138]. However, the
adaptations that occur in patients with obesity and type 2
diabetes following these interventions do not result in an
increased mtDNA content that is typical of mitochondrial
biogenesis in healthy muscle. In addition, mitochondria
from these individuals display abnormal morphology with
altered inner membrane cristae structure [45]. These results
are in keeping with the observation that the induction of
mitochondrial biogenesis in patients with this metabolicExperimental Diabetes Research 9
condition diﬀers from the molecular processes typically
observed in healthy individuals.
4.1.2. Macronutrient Modulation. The beneﬁcial eﬀects of
nutritional interventions on health and lifespan have been
known for decades. Nutrient deprivation by way of CR (20–
40% reduction) increases lifespan in a number of species
ranging from insects to mammals [139, 140]. The eﬃcacy
of CR in muscle is mediated by a variety of cellular and
molecular changes including increased mitochondrial bio-
genesis and reduced metabolic rate and ROS levels, as well as
increased mitochondrial autophagy [141–144]. Additionally,
CR alters substrate utilization in muscle from carbohydrate
metabolism towards a greater fatty acid oxidation [145]. The
eﬀects of CR have also been reported in humans albeit to a
lesser extent than in animals. Civitarese et al. showed that 6
months of 25% CR in healthy young individuals resulted in
increased mitochondrial biogenesis that was associated with
higher levels of SIRT1, PGC-1α, and Tfam protein. Skeletal
muscle from these subjects displayed increased mtDNA con-
tent along with decreased levels of DNA damage [146]. CR
(25%)hasalsobeenshowntoimproveinsulinsensitivityand
increasemitochondrialdensityandoxidativeenzymeactivity
in skeletal muscle from type 2 diabetic individuals [131].
Furthermore, prolonged CR in obese individuals with type
2 diabetes decreased myocardial triglyceride content that
was associated with improved myocardial function [147].
Thus, CR may be an eﬀective way to increase mitochondrial
biogenesis in a wide range of species and tissues; however,
more studies are required to characterize its role in insulin
signaling in muscle from type 2 diabetics.
4.1.3. Pharmacological Stimulation of Mitochondrial Biogen-
esis. In an eﬀort to reduce the severity of insulin resistance
and the clinical phenotype associated with type 2 diabetes,
diﬀerent classes of drugs have been developed that stim-
ulate/induce mitochondrial biogenesis and morphogenesis.
Peroxisome proliferator-activated receptors (PPARs) are a
family of nuclear hormone receptors that mediate the
expression of a wide array of genes involved in glucose and
fat metabolism. Modulation of the PPAR-activated pathway
may have therapeutic potential for metabolic disorders. For
example, thiazolidinediones (TZDs), such as rosiglitazone,
troglitazone, and pioglitazone, are classiﬁed as PPARγ ago-
nists that improve insulin sensitivity by increasing substrate
metabolism and reducing FFA levels and ROS production
[148, 149]. The PPAR agonist bezaﬁbrate has been shown
to increase mitochondrial enzyme activity, as well as the
levels of several respiratory chain subunit proteins in human
ﬁbroblasts with respiratory chain deﬁciency [150].
Another class of drugs gaining wide acceptance in
the treatment of diabetes are sirtuin 1 (SIRT1) activators.
Transgenic mice overexpressing SIRT1 display lower whole-
bodyenergyrequirementsandhavedecreasedratesofoxygen
consumption resulting in higher metabolic eﬃciency when
compared to their wild-type littermates. Additionally, these
animals display decreased susceptibility to the development
of diabetes [63]. The therapeutic potential of resveratrol,
a polyphenolic extract from grape skins and red wine, has
been gaining increasing popularity as a CR mimetic due
to its ability to induce mitochondrial biogenesis via SIRT1-
mediated activation of PGC-1α in mice. Furthermore, these
mice have improved insulin sensitivity and are refractory
to high-fat diet-induced obesity [151, 152]. Small SIRT1
activator molecules appear to mimic the eﬀe c to fC Rb y
altering the expression of target genes involved in substrate
metabolismandantioxidantdefensestherebyimprovingme-
tabolic function [151, 152]. In a recent study by Milne
et al. [153], obese animals treated with small SIRT1 activator
molecules were shown to display enhanced mitochondrial
function and improved insulin sensitivity, indicating the
potential use of these drugs in the treatment of type 2
diabetes.
Another group of mitochondrial biogenesis-stimulating
agents showing therapeutic promise are AMPK activators
such as 5-aminoimidazole-4-carboxamide-1-β-d-ribofura-
noside (AICAR) and metformin. The addition of AICAR
to C2C12 myoblasts upregulated PGC-1α gene expression
through SIRT1 [154], at least in part via transcriptional acti-
vation [155]. The administration of AICAR or metformin
improved insulin resistance and delayed the onset of diabetes
[156, 157]. Furthermore, metformin has been shown to
improve insulin sensitivity and has been consistently used
as an antidiabetic agent [158]. Thus, AMPK activators have
shown great promise as a pharmacological intervention
for type 2 diabetes, and future studies in this area will
further our understanding of AMPK signaling pathways and
promote the development of additional potentially eﬀective
antidiabetic agents.
5. Concluding Remarks
It is well established that mitochondria are intricately
involved in the pathogenesis of type 2 diabetes. This is
because of the instrumental role that mitochondria play
in lipid and carbohydrate metabolism, their morphological
and functional plasticity in response to inactivity and
disease, and their involvement in apoptosis and autophagy.
Whether the alterations observed in mitochondrial function
are a cause, or a consequence, of insulin resistance and
type 2 diabetes remains under debate. Despite the fact
that there is conﬂicting evidence regarding the extent of
mitochondrial dysfunction in type 2 diabetics, there is a
consensus among studies that skeletal muscle mitochondria
from diabetic animals or humans exhibit impairments in
key transcriptional regulators. In addition, alterations in
genes involved in mitochondrial fusion and ﬁssion, as
well as aberrant mitochondrial morphology, are commonly
associated with the increased production of ROS and the
accumulation of damaged DNA, proteins, and lipids. Col-
lectively, these transcriptional alterations can impair insulin
signaling pathways leading to insulin resistance and the
development of type 2 diabetes (Figure 3). The potential
to stimulate mitochondrial biogenesis and morphogenesis
through physiological interventions such as exercise, CR, or
pharmacological mimetics of mitochondrial biogenesis has
shown great promise in improving insulin sensitivity and10 Experimental Diabetes Research
Lipid accumulation
Altered mitochondrial
fusion and ﬁssion
Mitochondrial
dysregulation
Exercise
CR
TZDs
RSV
↓ Oxidative capacity
↑ ROS
Type 2 diabetes
Transcriptional regulators
(↓ PGC-1α, SIRT1)
Impaired insulin signaling/
insulin resistance
Oxidative stress
Obesity
Inactivity
Figure 3: Simpliﬁed scheme that illustrates the role of mitochondrial dysregulation in the pathogenesis of type 2 diabetes in skeletal muscle.
Obesity and physical inactivity can result in mitochondrial dysregulation through alterations in crucial transcriptional activators (e.g., PGC-
1α and SIRT1), as well as impaired fusion and ﬁssion leading to aberrant mitochondrial morphology. These changes can subsequently lead
to reduced oxidative capacity and cause lipid metabolite accumulation, increased oxidative stress, and the production of reactive oxygen
species (ROS). Over time, the accumulation of ROS can damage DNA, proteins, and lipids, further exacerbating mitochondrial dysfunction.
Collectively, these factors contribute to impaired insulin signaling pathways and increase the risk of type 2 diabetes. On the other hand,
physiological interventions, including exercise and caloric restriction (CR), as well as pharmacological agents such as thiazolidinediones
(TZDs)andresveratrol(RSV)havebeenshowntostimulatemitochondrialbiogenesisandreducemitochondrialdysfunctionthatisobserved
with type 2 diabetes in muscle.
attenuatingtheclinicalphenotypeassociatedwiththesemet-
abolic disorders. Thus, the closer we come to understanding
the molecular mechanisms governing these pathways during
normal physiological conditions, the better chance we have
to develop new therapeutic strategies that may one day pre-
vent or treat type 2 diabetes.
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